Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation technique effective enough to treat it. Omega 3 fatty acids have electrophysiological, autonomic modulation and anti-inflammatory effects. In addition, they are well tolerated, which altogether makes them worth testing in the context of AF. 586 were randomized to 1 gr/day of Omega 3 or placebo. The primary efficacy end point was sinus rhythm. At 12 months follow up, AF free survival rate was similar in both groups HR: 1,28 (0,77-1,89); p=0,1.
Conclusion: Supplements with Omega 3 do not have a major role in the secondary prevention of AF.
Comment: this study finally randomized less than half of the patients enrolled. Lower doses of Omega 3, compared to previous studies, a low risk of recurrence and a 60% use of amiodarone largely limited results. Despite limitations, Omega 3 fatty acids do not seem to have a clear effect on AF, secondary prevention or other contexts.
Alejandro Macchia
2012-11-05
Original title: Randomized, double blind, placebo-controlled, study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation – FORWARD Trial.
